Patents by Inventor Catherine R. Ferenz

Catherine R. Ferenz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NOVEL THIENOPYRROLE COMPOUNDS
    Publication number: 20110152243
    Abstract: The invention provides a compound of Formula (I) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological and oncological conditions.
    Type: Application
    Filed: December 21, 2010
    Publication date: June 23, 2011
    Applicant: ABBOTT LABORATORIES
    Inventors: Neil Wishart, Theresa Dunstan, Jeremy J. Edmunds, Anna M. Ericsson, Catherine R. Ferenz, Adrian D. Hobson, David C. Ihle, Kent D. Stewart, Lei Wang, Lu Wang
  • Modified interleukin-1&bgr; converting enzyme with increased stability
    Patent number: 6524807
    Abstract: Modified forms of human interleukin-1&bgr; converting enzyme (ICE) that display proteolytic activity and, furthermore, have increased stability compared to unmodified human ICE are disclosed. Nucleic acid molecules encoding a modified p10 subunit of ICE, and recombinant vectors and host cells incorporating such nucleic acid molecules, are also disclosed. A modified ICE protein of the invention can be used to cleave proteolytically ICE substrates and to identify modulators of ICE activity in screening assays. Moreover, due to its enhanced stability, the modified ICE of the invention is particularly suitable for use in the preparation of ICE crystals for X-ray crystallography.
    Type: Grant
    Filed: April 6, 2001
    Date of Patent: February 25, 2003
    Assignee: BASF Aktiengellschaft
    Inventors: Robert V. Talanian, John A. Mankovich, Tariq Ghayur, Catherine R. Ferenz
  • Modified interleukin-1beta converting enzyme with increased stability
    Publication number: 20020164762
    Abstract: Modified forms of human interleukin-1&bgr; converting enzyme (ICE) that display proteolytic activity and, furthermore, have increased stability compared to unmodified human ICE are disclosed. Nucleic acid molecules encoding a modified p10 subunit of ICE, and recombinant vectors and host cells incorporating such nucleic acid molecules, are also disclosed. A modified ICE protein of the invention can be used to cleave proteolytically ICE substrates and to identify modulators of ICE activity in screening assays. Moreover, due to its enhanced stability, the modified ICE of the invention is particularly suitable for use in the preparation of ICE crystals for X-ray crystallography.
    Type: Application
    Filed: April 6, 2001
    Publication date: November 7, 2002
    Applicant: BASF Aktiengesellschaft
    Inventors: Robert V. Talanian, John A. Mankovich, Tariq Ghayur, Catherine R. Ferenz
  • Modified interleukin-1&bgr; converting enzyme with increased stability
    Patent number: 6242240
    Abstract: Modified forms of human interleukin-1&bgr; converting enzyme (ICE) that display proteolytic activity and, furthermore, have increased stability compared to unmodified human ICE are disclosed. Nucleic acid molecules encoding a modified p10 subunit of ICE, and recombinant vectors and host cells incorporating such nucleic acid molecules, are also disclosed. A modified ICE protein of the invention can be used to cleave proteolytically ICE substrates and to identify modulators of ICE activity in screening assays. Moreover, due to its enhanced stability, the modified ICE of the invention is particularly suitable for use in the preparation of ICE crystals for X-ray crystallography.
    Type: Grant
    Filed: February 9, 1999
    Date of Patent: June 5, 2001
    Assignee: BASF Aktiengellschaft
    Inventors: Robert V. Talanian, John A. Mankovich, Tariq Ghayur, Catherine R. Ferenz
  • Modified interleukin-1.beta. converting enzyme with increased stability
    Patent number: 5869315
    Abstract: Modified forms of human interleukin-1.beta. converting enzyme (ICE) that display proteolytic activity and, furthermore, have increased stability compared to unmodified human ICE are disclosed. Nucleic acid molecules encoding a modified p10 subunit of ICE, and recombinant vectors and host cells incorporating such nucleic acid molecules, are also disclosed. A modified ICE protein of the invention can be used to cleave proteolytically ICE substrates and to identify modulators of ICE activity in screening assays. Moreover, due to its enhanced stability, the modified ICE of the invention is particularly suitable for use in the preparation of ICE crystals for X-ray crystallography.
    Type: Grant
    Filed: December 18, 1995
    Date of Patent: February 9, 1999
    Assignee: BASF Aktiengesellschaft
    Inventors: Robert V. Talanian, John A. Mankovich, Tariq Ghayur, Catherine R. Ferenz
  • Compositions for expression of proteins in host cells using a preprocollagen signal sequence
    Patent number: 5712114
    Abstract: Hybrid genes comprising a nucleotide sequence encoding a preprocollagen signal sequence operatively linked to a nucleotide sequence encoding a heterologous protein are disclosed. The hybrid genes are useful for secretion of heterologous proteins from host cells. In a preferred embodiment, the signal sequence of the human preprocollagen .alpha.1(I) protein is linked to a heterologous protein of interest to allow for secretion of the protein from Hansenula polymorpha cells.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: January 27, 1998
    Assignee: BASF Aktiengesellschaft
    Inventors: John A. Mankovich, Linda Hammill, Catherine R. Ferenz